Binding of betaxolol, metoprolol and oligonucleotides to synthetic and bovine ocular melanin, and prediction of drug binding to melanin in human choroid-retinal pigment epithelium

Pharmaceutical Research

Volumn 24, Issue 11, 2007, Pages 2063-2070

  Pitkänen, Leena ^a,b   Ranta, Veli Pekka ^a   Moilanen, Hanna ^a   Urtti, Arto ^a,c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Beta blocker; Binding; Choroid; Melanin; RPE

Indexed keywords

6 CARBOXYFLUORESCEIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; FLUORESCEIN ISOTHIOCYANATE; MELANIN; METOPROLOL TARTRATE; OLIGONUCLEOTIDE;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CHOROID; COMPARATIVE STUDY; CONCENTRATION RESPONSE; COW; DRUG PROTEIN BINDING; LASER DIFFRACTION; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BETAXOLOL; CATTLE; CHOROID; HUMANS; MELANINS; METOPROLOL; OLIGONUCLEOTIDES; PIGMENT EPITHELIUM OF EYE;

EID: 34848825640     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9342-0     Document Type: Article

References (32)

1. S. Ito. Re-examination of the structure of melanin. Biochim. Biophys. Acta. 883:155-161 (1986).
2. T. Sarna. Properties and function of the ocular melanin-a photobiological view. J. Photochem. Photobiol. B. 12:215-58 (1992).
3. M. Boulton. Melanin and the retinal pigment epithelium. In: M. J. Marmor and T. J. Wolfensberger (eds.), Retinal Pigment Epithelium, Oxford University Press, New York, 1998, pp. 68-85.
4. R. M. J. Ings. The melanin binding of drugs and its implications. Drug Metab. Rev. 15:1183-1212 (1984).
5. B. S. Larsson. Interaction between chemicals and melanin. Pigment. Cell Res. 6:127-133 (1993).
6. B. Leblanc, S. Jezequel, T. Davies, G. Hanton, and C Taradach. Binding of drugs to eye melanin is not predictive of ocular toxicity. Regul. Toxicol. Pharmacol. 28:124-132 (1998).
7. M. Salazar and P. N. Patil. An explanation for the long duration of mydriatic effect of atropine in eye. Invest. Ophthalmol. 15:671-673 (1976).
8. L. Salminen and A. Urtti. Disposition of ophthalmic timolol in treated and untreated rabbit eyes. A multiple and single dose study. Exp. Eye Res. 38:203-206 (1984).
9. L. Salminen, G. Imre and R. Huupponen. The effect of ocular pigmentation on intraocular pressure response to timolol. Acta. Ophthalmol. Suppl. 173:15-18 (1985).
10. A. Urtti, L. Salminen, H. Kujari and V. Jäntti. Effect of ocular pigmentation on pilocarpine pharmacology in the rabbit eye. II. Drug response. Int. J. Pharm. 19:53-61 (1984).
11. L. Pitkanen, V. P. Ranta, H. Moilanen and A. Urtti. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest. Ophthalmol. Vis. Sci. 46:641-646 (2005).
12. A. M. Potts. The reaction of uveal pigment in vitro with polycyclic compounds. Invest. Ophthalmol. 3:405-416 (1964).
13. B. Larsson and H. Tjälve. Studies on the mechanism of drug binding to melanin. Biochem. Pharmacol. 28:1181-1187 (1979).
14. J. B. Nofsinger, S. E. Forest, L. M. Eibest, K. A. Gold, and J. D. Simon. Probing the building blocks of eumelanins using scanning electron microscopy. Pigment. Cell Res. 13:179-184 (2000).
15. M. J. Koeberle, P. M. Hughes, G. G. Skellern and C. G. Wilson. Binding of memantine to melanin: influence of type of melanin and characteristics. Pharm. Res. 20:1702-9 (2003).
16. M. J. Sauer and S. P. Anderson. In vitro and in vivo studies of drug residue accumulation in pigmented tissues. Analyst. 119:2553-2556 (1994).
17. M. Seiji, T. B. Fitzpatrick, and M. S. Birbeck. The melanosome: a distinctive subcellular particle of mammalian melanocytes and the site of melanogenesis. J Invest Dermatol. 36:243-252 (1961).
18. M. Boulton and J. Marshall. Repigmentation of human retinal pigment epithelial cells in vitro. Exp. Eye. Res. 41:209-218 (1985).
19. V. P. Ranta, E. Toropainen, A. Talvitie, S. Auriola, and A. Urtti. Simultaneous determination of eight beta-blockers by gradient high-performance liquid chromatography with combined ultraviolet and fluorescence detection in corneal permeability studies in vitro. J. Chromatogr. B. 772:81-87 (2002).
20. I. A. Menon, D. C. Wakeham, S. D. Persad, M. Avaria, G. Trope, and P. K. Basu. Quantitative determination of the melanin contents in ocular tissues from human blue and brown eyes. J. Ocul. Pharmacol. 8:35-42 (1992).
21. G. Hollo, J. T. Whitson, R. Faulkner, B. Mc Cue, M. Curtis, H. Wieland, J. Chastain, M. Sanders, L. De Santis, J. Przydraga, and D. C. Dahlin. Concentrations of betaxolol in ocular tissues of patients with glaucoma and normal monkeys after 1 month of topical ocular administration. Invest. Ophthalmol. Vis. Sci. 47:235-240 (2006).
22. R. Fux, K. Morike, A. M. Prohmer, U. Dalabar, M. Schwab, E. Schaeffeler, G. Lorenz, C.H. Gleiter, M. Eichelbaum, and K. T. Kivisto. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin. Pharmacol. Ther. 78:378-387 (2005).
23. M. Boulton, F. Docchio, P. Dayhaw-Barker, R. Ramponi, and R. Cubeddu. Age-related changes in the morphology, absorption and fluorescence of melanosomes and lipofuscin granules of the retinal pigment epithelium. Vision Res. 30:1291-1303 (1990).
24. Y. Liu, L. Hong, K. Wakamatsu, S. Ito, B. B. Adhyaru, C. Y. Cheng, C. R. Bowers, and J. D. Simon. Comparisons of the structural and chemical properties of melanosomes isolated from retinal pigment epithelium, iris and choroid of newborn and mature bovine eyes. Photochem. Photobiol. 81:510-516 (2005).
25. T. Abrahamsson, S. Boström, J. Bräutigam, P. O. Lagerström, C. G. Regårdh, and G. Vauqelin. Binding of the beta-blockers timolol and H 216/44 to ocular melanin. Exp. Eye Res. 47:565-577 (1988).
26. P. E. Rakoczy, M. C. Lai, M. Watson, U. Seydel, and I. Constable. Targeted delivery of an antisense oligonucleotide in the retina: uptake, distribution, stability, and effect. Antisense Nucleic Acid Drug Dev. 6:207-13 (1996).
27. J. Chastain. General considerations in ocular drug therapy. In A. K. Mitra (ed.), Drug delivery systems, Marcel Dekker, New York, 2003, pp. 59-107.
28. C. M. Perry and J. A. Balfour. Fomivirsen. Drugs 57:375-81 (1999).
29. N. P. S. Cheruvu and U. B Kompella. Bovine and porcine transscleral solute transport: influence of lipohilicity and the choroid-Bruch's layer. Invest. Ophthalmol. Vis. Sci. 47:4513-4522 (2006).
30. N. P. Cheruvu, A. C. Amrite, and U. B. Kompella. Effect of eye pigmentation and diabetes on transscleral drug delivery. Invest. Ophthalmol. Vis. Sci. 47: E-abstract 4470 (2006)
31. P. Dayhaw Parker, W. Unger, E. Bouma, and M. Boulton. Binding characteristics of drugs to melanin granules from human RPE. Invest. Ophthalmol. Vis. Sci. 29(Suppl.):285 (1988).
32. I. A. Menon, G. E. Trope, P. K. Basu, D. C.Wakeham, and S. D. Persad. Binding of timolol to iris-ciliary body and melanin: an in vitro model for assessing the kinetics and efficacy of long-acting antiglaucoma drugs. J. Ocul. Pharmacol. 5:313-24 (1989).